Significance of systemic mast cell disease with associated hematologic disorders - PubMed (original) (raw)
Significance of systemic mast cell disease with associated hematologic disorders
W D Travis et al. Cancer. 1988.
Abstract
A clinical and hematopathologic review of 66 patients with systemic mast cell disease (SMCD) was undertaken to investigate the frequency and the clinical significance of associated hematologic disorders. Twenty-two patients were found to have a second hematologic disorder, 19 of which involved the myeloid cells (ten dysmyelopoietic syndromes, five myeloproliferative disorders, three acute nonlymphocytic leukemias, and one chronic neutropenia), and three of which involved the lymphoid cells (three malignant lymphomas). A chromosome analysis of the bone marrow revealed abnormalities characteristic of neoplastic myeloid disorders in four patients. Five-year survival for patients with hematologic disorders was 28% compared with 61% for other SMCD patients (P = 0.004). Patients with hematologic disorders differed significantly from other SMCD patients in that they were about 7 years older (P = 0.039), and they presented more commonly with anemia (P less than 0.001) and constitutional symptoms (P = 0.007). These patients also had less frequent skin symptoms (P = 0.003) and urticaria pigmentosa (P = 0.018). By definition, patients with hematologic disorders had a greater percent of hematopoiesis (P less than 0.001) and decreased fat cells (P = 0.011) on bone marrow biopsies. A multivariate model demonstrated that the following independent variables were associated with the presence of hematologic disorders: low hemoglobin (P = 0.001), the absence of hepatomegaly (P = 0.016), high leukocyte count (P = 0.021), and the presence of pathologic fractures (P = 0.051). The frequent coexistence of SMCD with dysplastic and neoplastic disorders of myeloid cells is consistent with the concept that SMCD itself is a disorder of myeloid cells and that the mast cell may be myeloid in origin.
Similar articles
- Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis.
Lawrence JB, Friedman BS, Travis WD, Chinchilli VM, Metcalfe DD, Gralnick HR. Lawrence JB, et al. Am J Med. 1991 Dec;91(6):612-24. doi: 10.1016/0002-9343(91)90214-i. Am J Med. 1991. PMID: 1750431 - Hematologic aspects of systemic mastocytosis.
Parker RI. Parker RI. Hematol Oncol Clin North Am. 2000 Jun;14(3):557-68. doi: 10.1016/s0889-8588(05)70296-3. Hematol Oncol Clin North Am. 2000. PMID: 10909040 Review. - [Systemic mastocytosis and secondary acute myeloid leukemia].
Galán Alvarez P, Ibáñez García J, Funes Vera C, López García-Carreño MD, Alix Trueba A, Pérez Guillermo M, Alberola C. Galán Alvarez P, et al. An Med Interna. 1999 Sep;16(9):466-8. An Med Interna. 1999. PMID: 10609361 Review. Spanish. - Hematologic aspects of mastocytosis: II: management of hematologic disorders in association with systemic mast cell disease.
Parker RI. Parker RI. J Invest Dermatol. 1991 Mar;96(3):52S-53S; discussion 53S-54S. J Invest Dermatol. 1991. PMID: 2002265 - Splenectomy in the management of systemic mast cell disease.
Friedman B, Darling G, Norton J, Hamby L, Metcalfe D. Friedman B, et al. Surgery. 1990 Jan;107(1):94-100. Surgery. 1990. PMID: 2404352 Clinical Trial.
Cited by
- A Rare Case of Systemic Mastocytosis with Associated Hematologic Neoplasm (SM-AHN) Involving Chronic Myeloid Leukemia: A Case Report and Literature Review.
Ibrahim FA, Abdulla MAJ, Soliman D, Al Sabbagh A, Nawaz Z, Akiki SJ, Shwaylia H, Yassin MA. Ibrahim FA, et al. Am J Case Rep. 2020 May 13;21:e923354. doi: 10.12659/AJCR.923354. Am J Case Rep. 2020. PMID: 32398637 Free PMC article. Review. - The Spectrum of Aggressive Mastocytosis: A Workshop Report and Literature Review.
Leguit R, Hebeda K, Kremer M, van der Walt J, Gianelli U, Tzankov A, Orazi A. Leguit R, et al. Pathobiology. 2020;87(1):2-19. doi: 10.1159/000504099. Epub 2019 Dec 4. Pathobiology. 2020. PMID: 31802761 Free PMC article. Review. - Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report.
Malik F, Ali N, Jafri SIM, Ghani A, Hamid M, Boigon M, Fidler C. Malik F, et al. J Med Case Rep. 2017 Apr 24;11(1):119. doi: 10.1186/s13256-017-1278-3. J Med Case Rep. 2017. PMID: 28438191 Free PMC article. - Systemic Mastocytosis with Smoldering Multiple Myeloma: Report of a Case.
Ghanem S, Garcia G, Ying L, Hurford M, Odaimi M. Ghanem S, et al. Case Rep Oncol Med. 2016;2016:3161768. doi: 10.1155/2016/3161768. Epub 2016 May 16. Case Rep Oncol Med. 2016. PMID: 27293930 Free PMC article. - Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis.
De Vita S, Schneider RK, Garcia M, Wood J, Gavillet M, Ebert BL, Gerbaulet A, Roers A, Levine RL, Mullally A, Williams DA. De Vita S, et al. PLoS One. 2014 May 2;9(5):e96209. doi: 10.1371/journal.pone.0096209. eCollection 2014. PLoS One. 2014. PMID: 24788138 Free PMC article.
MeSH terms
LinkOut - more resources
Medical